Treatment News : FDA Approves Sustiva for Children 3 Months to 3 Years Old

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

May 8, 2013

FDA Approves Sustiva for Children 3 Months to 3 Years Old

Broadening pediatric treatment options, the U.S. Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Sustiva (efavirenz) for use in HIV-positive children 3 months to 3 years old and weighing at least 7.7 pounds (3.5 kilograms). The approval of the antiretroviral’s expanded pediatric use (ARV) also came with dosing recommendations, including a “capsule sprinkle” administration meant for those who cannot swallow capsules or tablets.

Sustiva, which is a non-nucleotide reverse transcriptase inhibitor, was approved in 1998 for HIV-positive children 3 years of age or older and weighing at least 22 pounds (10 kg).

The expanded approval was based upon three open-label trials evaluating the pharmacokinetics, safety and ARV activity of Sustiva in combination with other ARVs in 182 treatment-naive and treatment-experienced HIV-positive pediatric study participants between 3 months and 21 years old. With a median observation of 123 weeks, investigators found that the drug lowered viral load and led to a rise in CD4 counts across all ages.

Rates of adverse reactions were similar to those found in studies of adults taking Sustiva, with the exception of an increase in rash, experienced by 32 percent of the participants, and which was more likely to be severe. Five of the children (2.7 percent) dropped out of the study because of the rash.

To read a Bristol-Myers Squibb release, click here.

To read the FDA labeling update, click here.

Search: Sustiva, efavirenz, pediatric, U.S. Food and Drug Administration, FDA, Bristol-Myers Squibb, capsule sprinkle.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    soy_Ric
    Rochester
    New York


    Deelight4u
    BROOKLYN
    New York


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.